TxCell develops cellular immunotherapy platforms based on antigen-specific regulatory T cells. The Company's products are used for the treatment of severe autoimmune and inflammatory diseases, as well as transplantation-related inflammatory disorders.

TypeSubsidiary
HQValbonne, FR
Founded2001
Websitetxcell.com
Cybersecurity ratingBMore
TxCell was founded in 2001 and is headquartered in Valbonne, FR

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at TxCell

Stephane Boissel

Stephane Boissel

CEO
Raphael Flipo

Raphael Flipo

SVP, Chief Financial Officer
Francois Meyer

Francois Meyer

Chairman of the Board and Head of Research
Show more

TxCell Office Locations

TxCell has an office in Valbonne
Valbonne, FR (HQ)
Allée de la Nertière
Show all (1)

TxCell Financials and Metrics

Summary Metrics

Founding Date

2001

Total Funding

$71.6 m

Investors

TxCell Revenue

TxCell's revenue was reported to be €2.23 m in FY, 2017 which is a 24.2% decrease from the previous period.
Annual
EURFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3.4m4.6m2.9m2.2m

Revenue growth, %

36%(36%)(24%)

General and administrative expense

2.2m3.5m4.5m3.2m

R&D expense

7.8m10.8m10.5m8.5m
Half Year
EURH1, 2015H1, 2016H1, 2017H1, 2018

Revenue

2.0m1.4m1.3m1.0m

General and administrative expense

1.9m2.5m1.8m1.9m

R&D expense

5.7m5.6m3.9m4.7m

Operating expense total

7.6m8.1m5.7m6.8m
Annual
EURFY, 2014FY, 2015FY, 2016FY, 2017

Cash

13.9m9.2m3.5m4.9m

Accounts Receivable

1.0m4.0k4.0k

Current Assets

18.5m13.8m5.8m7.5m

PP&E

1.4m876.0k736.0k625.0k
Half Year
EURH1, 2015H1, 2016H1, 2017

Cash

7.7m3.2m8.7m

Accounts Receivable

233.0k4.0k7.0k

Current Assets

13.3m7.3m11.3m

PP&E

1.3m836.0k631.0k
Annual
EURFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(8.3m)(11.3m)(13.6m)(10.9m)

Depreciation and Amortization

460.0k1.1m(326.0k)272.0k

Accounts Payable

5.8m213.0k(714.0k)(19.0k)

Cash From Operating Activities

(6.9m)(10.1m)(10.4m)(9.8m)
Half Year
EURH1, 2015H1, 2016H1, 2017

Net Income

(5.7m)(7.1m)(5.3m)

Depreciation and Amortization

257.0k(445.0k)107.0k

Accounts Payable

(146.0k)503.0k219.0k

Cash From Operating Activities

(6.3m)(6.1m)(5.1m)
EURFY, 2014

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.4 x
Show all financial metrics

TxCell Operating Metrics

FY, 2015FY, 2016FY, 2017

Patents Licensed

125200170
Show all operating metrics

TxCell Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

TxCell Online and Social Media Presence

Embed Graph

TxCell News and Updates

Sangamo Therapeutics to Acquire TxCell

RICHMOND, Calif. and VALBONNE, France, July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and TxCell S.A. (ENXTPA: TXCL) announced today that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the ...

TxCell Blogs

Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

BRISBANE, Calif. --(BUSINESS WIRE)--May 24, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021 . Ms.

Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference

BRISBANE, Calif. --(BUSINESS WIRE)--May 21, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4 th at 11am Eastern Time .

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time   BRISBANE, Calif. --(BUSINESS WIRE)--May 4, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results.

Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy

BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 27, 2021-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 11-14, 2021 , in a virtual form…

Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast

BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 27, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2021 financial results after the market closes on Tuesday, May 4, 2021 .

Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease

Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease Content Import Thu, 03/25/2021 - 08:31 Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease …
Show more

TxCell Frequently Asked Questions

  • When was TxCell founded?

    TxCell was founded in 2001.

  • Who are TxCell key executives?

    TxCell's key executives are Stephane Boissel, Raphael Flipo and Francois Meyer.

  • How many employees does TxCell have?

    TxCell has 17 employees.

  • What is TxCell revenue?

    Latest TxCell annual revenue is €2.2 m.

  • What is TxCell revenue per employee?

    Latest TxCell revenue per employee is €131.4 k.

  • Who are TxCell competitors?

    Competitors of TxCell include Bioz, Karius and eGenesis.

  • Where is TxCell headquarters?

    TxCell headquarters is located at Allée de la Nertière, Valbonne.

  • Where are TxCell offices?

    TxCell has an office in Valbonne.

  • How many offices does TxCell have?

    TxCell has 1 office.